Cybrexa Therapeutics

3 three
Biotech

Exelixis goes 3 in 3 with $30M for 3 Catalent programs

Exelixis has made its third deal in three days, this time paying Catalent Biologics $30 million cash for licensing rights to three ADCs.
Gabrielle Masson Nov 3, 2022 1:20pm
forward money growth

Busy day for Exelixis with 2 new deals worth $937M+ in biobucks

Nov 1, 2022 7:20pm
cancer newspaper

Yale spinout targets cancer's acidic environment to boost I-O

Oct 7, 2021 9:00am